CASBF
Price
$5.60
Change
+$0.30 (+5.66%)
Updated
Oct 27 closing price
Capitalization
1.86B
Intraday BUY SELL Signals
CPHRF
Price
$9.83
Change
+$0.30 (+3.15%)
Updated
Nov 18 closing price
Capitalization
244.81M
112 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CASBF vs CPHRF

Header iconCASBF vs CPHRF Comparison
Open Charts CASBF vs CPHRFBanner chart's image
CANSINO BIOLOGICS
Price$5.60
Change+$0.30 (+5.66%)
Volume$151
Capitalization1.86B
Cipher Pharmaceuticals
Price$9.83
Change+$0.30 (+3.15%)
Volume$5.06K
Capitalization244.81M
CASBF vs CPHRF Comparison Chart in %
CASBF
Daily Signal:
Gain/Loss:
CPHRF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CASBF vs. CPHRF commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CASBF is a Hold and CPHRF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (CASBF: $5.60 vs. CPHRF: $9.83)
Brand notoriety: CASBF and CPHRF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CASBF: 85% vs. CPHRF: 32%
Market capitalization -- CASBF: $1.86B vs. CPHRF: $244.81M
CASBF [@Pharmaceuticals: Generic] is valued at $1.86B. CPHRF’s [@Pharmaceuticals: Generic] market capitalization is $244.81M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CASBF’s FA Score shows that 1 FA rating(s) are green whileCPHRF’s FA Score has 1 green FA rating(s).

  • CASBF’s FA Score: 1 green, 4 red.
  • CPHRF’s FA Score: 1 green, 4 red.
According to our system of comparison, both CASBF and CPHRF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CASBF’s TA Score shows that 4 TA indicator(s) are bullish while CPHRF’s TA Score has 4 bullish TA indicator(s).

  • CASBF’s TA Score: 4 bullish, 1 bearish.
  • CPHRF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CASBF is a better buy in the short-term than CPHRF.

Price Growth

CASBF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while CPHRF (@Pharmaceuticals: Generic) price change was +1.87% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.77%. For the same industry, the average monthly price growth was -6.55%, and the average quarterly price growth was +28.28%.

Reported Earning Dates

CPHRF is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.77% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CASBF($1.86B) has a higher market cap than CPHRF($245M). CASBF YTD gains are higher at: 39.965 vs. CPHRF (-3.398). CPHRF has higher annual earnings (EBITDA): 16.7M vs. CASBF (-1.88B). CASBF has more cash in the bank: 4.02B vs. CPHRF (11.3M). CPHRF has less debt than CASBF: CPHRF (25.5M) vs CASBF (2.12B). CASBF has higher revenues than CPHRF: CASBF (359M) vs CPHRF (47.6M).
CASBFCPHRFCASBF / CPHRF
Capitalization1.86B245M758%
EBITDA-1.88B16.7M-11,277%
Gain YTD39.965-3.398-1,176%
P/E RatioN/A14.37-
Revenue359M47.6M754%
Total Cash4.02B11.3M35,531%
Total Debt2.12B25.5M8,306%
FUNDAMENTALS RATINGS
CASBF vs CPHRF: Fundamental Ratings
CASBF
CPHRF
OUTLOOK RATING
1..100
4254
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10033
SMR RATING
1..100
9560
PRICE GROWTH RATING
1..100
4260
P/E GROWTH RATING
1..100
8054
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CASBF's Valuation (9) in the null industry is somewhat better than the same rating for CPHRF (61). This means that CASBF’s stock grew somewhat faster than CPHRF’s over the last 12 months.

CPHRF's Profit vs Risk Rating (33) in the null industry is significantly better than the same rating for CASBF (100). This means that CPHRF’s stock grew significantly faster than CASBF’s over the last 12 months.

CPHRF's SMR Rating (60) in the null industry is somewhat better than the same rating for CASBF (95). This means that CPHRF’s stock grew somewhat faster than CASBF’s over the last 12 months.

CASBF's Price Growth Rating (42) in the null industry is in the same range as CPHRF (60). This means that CASBF’s stock grew similarly to CPHRF’s over the last 12 months.

CPHRF's P/E Growth Rating (54) in the null industry is in the same range as CASBF (80). This means that CPHRF’s stock grew similarly to CASBF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CASBFCPHRF
RSI
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
49%
Bearish Trend 2 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
69%
Advances
ODDS (%)
N/A
Bullish Trend 2 days ago
80%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
CASBF
Daily Signal:
Gain/Loss:
CPHRF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CENTX14.00N/A
N/A
Centerstone Investors I
LCCCX32.14N/A
N/A
Columbia Contrarian Core C
GISTX40.26N/A
N/A
Goldman Sachs Technology Opps Inv
PRDAX12.18N/A
N/A
Principal Diversified Real Asset A
WOOPX16.90-0.01
-0.06%
JPMorgan SMID Cap Equity I

CASBF and

Correlation & Price change

A.I.dvisor tells us that CASBF and CRLBF have been poorly correlated (+3% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CASBF and CRLBF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CASBF
1D Price
Change %
CASBF100%
N/A
CRLBF - CASBF
3%
Poorly correlated
-11.60%
CNTMF - CASBF
2%
Poorly correlated
-0.39%
BUDZ - CASBF
2%
Poorly correlated
+2.98%
CBWTF - CASBF
1%
Poorly correlated
-0.85%
CPHRF - CASBF
0%
Poorly correlated
-2.06%
More

CPHRF and

Correlation & Price change

A.I.dvisor tells us that CPHRF and OGI have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPHRF and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CPHRF
1D Price
Change %
CPHRF100%
-2.06%
OGI - CPHRF
23%
Poorly correlated
-2.58%
SDZNY - CPHRF
21%
Poorly correlated
-0.86%
CBWTF - CPHRF
8%
Poorly correlated
-0.85%
CURLF - CPHRF
5%
Poorly correlated
-2.10%
CRLBF - CPHRF
2%
Poorly correlated
-11.60%
More